Remedy Robotics

About Remedy Robotics

Remedy Robotics is a medical technology company founded in 2020 by cardiothoracic surgeon Dr. David Bell and Stanford-trained robotics expert Dr. Jake Sganga. The company is headquartered in San Francisco, CA, and has developed a remotely operable endovascular surgical robotic system to address the critical gap in access to timely treatment for cardiovascular emergencies like stroke and heart attack. Bell, who comes from a family of doctors and studied medicine and mathematics, conceived the idea during his MBA at Stanford, where he focused on machine learning and robotics. Sganga has a PhD from Stanford with expertise in surgical robotics, computer vision, and mechanical engineering.

The company's core product is the Remedy N1 System, a platform that combines proprietary robotics with AI-powered software, allowing specialist physicians to perform minimally invasive endovascular procedures from any location. This technology aims to solve the problem of geographic disparity in care, where only a small fraction of patients can access specialist centers in time. The system integrates into existing catheterization labs and gives a remote clinician control over multiple tools, including guidewires, catheters, and stents, using a portable console. AI-supported software enhances precision by fusing imaging data from CT, MRI, and fluoroscopy for real-time navigation.

Remedy Robotics has achieved significant milestones, including the world's first fully remote neurointerventional procedures in humans, conducted between two different hospitals in Toronto in late 2025. This demonstrated the system's capability to perform complex interventions without a specialist physically present, a crucial step toward making advanced care accessible in underserved areas. The company's business model focuses on deploying this system in hospitals, enabling them to offer advanced interventions regardless of on-site specialist availability. The technology targets a market where millions of people are affected by cardiovascular diseases but fewer than 3% have access to the gold-standard endovascular treatment. The company has raised $38 million in funding from investors including DCVC, Blackbird Ventures, and KdT Ventures to scale manufacturing and expand its AI capabilities.